Summary
RARE CANCERS: Charting a Faster Route to Treatment
Supported by The Economist Group
Brief Video Highlight
Friday, February 1, 2019
Rare cancers present doctors, researchers, and patients with a unique set of challenges. Rare cancers often are diagnosed at later stages. Patients typically have limited treatment options, in part because the small number of diagnoses makes gold-standard clinical trials difficult. The picture is further complicated by increasingly expensive cancer drug costs.
Yet, promises of emerging technologies, improved diagnostics, targeted therapies and pharmaceutical options provide hope. Calls for new ways to study rare cancers are being made so that patients can get access to better treatments more quickly.
In this Forum, panelists discussed how advances in cancer immunology, innovative trial designs, and international data sharing can create new hope for patients with rare cancers.
Part of: Policy Controversies.
Supported by The Economist Group
Background Articles
- Treating cancer: Progress on many fronts
The Economist - Tessa Jowell speech on Innovative Cancer Treatment & the NHS
House of Lords Labour - Inaugural Symposium: Reinventing Cancer Prevention and Early Detection for the 21st Century
Center for Global Cancer Prevention
Image Credit: Dylan Burnette and Jennifer Lippincott-Schwartz, NIH
